Sustained immunological effects of Glatiramer acetate in patients with multiple sclerosis treated for over 6 years (Q44090554)

29 November 2017

title

Sustained immunological effects of Glatiramer acetate in patients with multiple sclerosis treated for over 6 years (English)

1 reference

29 November 2017

0 references

Chen M

1

1 reference

29 November 2017

Conway K

2

1 reference

29 November 2017

Johnson KP

3

1 reference

29 November 2017

Martin R

4

1 reference

29 November 2017

Dhib-Jalbut S

5

1 reference

29 November 2017

publication date

1 September 2002

1 reference

Journal of the Neurological Sciences

29 November 2017

number of pages

7

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

29 November 2017

volume

201

1 reference

29 November 2017

issue

1-2

1 reference

29 November 2017

page(s)

71-77

1 reference

Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide

29 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0022-510X(02)00201-0

Suppression of experimental allergic encephalomyelitis in Rhesus monkeys by a synthetic basic copolymer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-510X(02)00201-0

Effect of treatment with copolymer 1 (Cop-1) on the in vivo and in vitro manifestations of experimental allergic encephalomyelitis (EAE)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-510X(02)00201-0

Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-510X(02)00201-0

A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-510X(02)00201-0

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-510X(02)00201-0

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-510X(02)00201-0

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-510X(02)00201-0

T suppressor hybridomas and interleukin-2-dependent lines induced by copolymer 1 or by spinal cord homogenate down-regulate experimental allergic encephalomyelitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-510X(02)00201-0

Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-510X(02)00201-0

Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-510X(02)00201-0

Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-510X(02)00201-0

Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-510X(02)00201-0

Multiple sclerosis: comparison of copolymer-1- reactive T cell lines from treated and untreated subjects reveals cytokine shift from T helper 1 to T helper 2 cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-510X(02)00201-0

Mechanisms of immunomodulation by glatiramer acetate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-510X(02)00201-0

Antigen-driven bystander suppression after oral administration of antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-510X(02)00201-0

Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen-presenting cells--specificity and promiscuity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-510X(02)00201-0

Binding of copolymer 1 and myelin basic protein leads to clustering of class II MHC molecules on antigen-presenting cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-510X(02)00201-0

Copolymer-1-induced inhibition of antigen-specific T cell activation: interference with antigen presentation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-510X(02)00201-0

Specific inhibition of the T-cell response to myelin basic protein by the synthetic copolymer Cop 1

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-510X(02)00201-0

Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-510X(02)00201-0

The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of copolymer 1 on MOG-induced disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-510X(02)00201-0

Treatment of multiple sclerosis with Copaxone (COP): Elispot assay detects COP-induced interleukin-4 and interferon-gamma response in blood cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-510X(02)00201-0

General method for the rapid solid-phase synthesis of large numbers of peptides: specificity of antigen-antibody interaction at the level of individual amino acids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-510X(02)00201-0

Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-510X(02)00201-0

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-510X(02)00201-0

Glatiramer acetate (Copaxone) therapy induces CD8( ) T cell responses in patients with multiple sclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/S0022-510X(02)00201-0

10.1016/S0022-510X(02)00201-0

7 January 2021

Identifiers

DOI

1 reference

29 November 2017

1 reference